Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01144754 · ClinicalTrials.gov registry record
Observational Study of Diffuse Large B Cell Primary Breast Lymphomas Treated With RCHOP +/- XRT
A clinical trial, sponsored by Stanford University.
- Terminated
- Registry status
- 1
- Enrollment target
NCT01144754: Clinical Trial study, sponsored by Stanford University.
NCT01144754 is a clinical trial that was terminated before completion, run by Stanford University. The registered enrollment target is 1 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01144754 was terminated before completion, sponsored by Stanford University.
- TERMINATED
- Registry status
- 1 participants
- Enrollment target
Study Summary
This is a multi-center observational study to assess addition of Rituximab in the treatment of previously untreated patients with Diffuse Large B-Cell Lymphomas(DLBCL) over an enrollment period of 60 months. Patients in this study are enrolling for the collection of their data on observations made during normal clinical practice.
Interventions
- DRUG Rituximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2009-02 |
| Est. Completion | 2012-04 |
Why NCT01144754 stopped before completion
NCT01144754 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 1 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Rituximab is the first listed.
NCT01144754 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01144754 about?
NCT01144754 is a clinical study titled "Observational Study of Diffuse Large B Cell Primary Breast Lymphomas Treated With RCHOP +/- XRT". This is a multi-center observational study to assess addition of Rituximab in the treatment of previously untreated patients with Diffuse Large B-Cell Lymphomas(DLBCL) over an enrollment period of 60 months. Patients in this study are enrolling for the collection of their data on observations made d...
What is the current status of trial NCT01144754?
This trial is currently terminated. The enrollment target is 1 participants. The study started on 2009-02. Estimated completion is 2012-04.
What interventions are being tested in trial NCT01144754?
The interventions under investigation include: Rituximab (DRUG).
Who is sponsoring clinical trial NCT01144754?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia